The Latest

  • COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
    • Autoimmune Diseases
    • Allergies
    • Rare Diseases
    • Gene Therapy
  • Our Clinical Trials
  • Publications & Media
    • Press Releases
    • Publications
  • Careers

Advancing Our Pipeline

Preclinical

Phase 1

Phase 2

Phase 3

Approval

Autoimmune & Gene Therapy

CNP-101/TAK-101 Celiac Disease Takeda Partnership

CNP-104 Primary Biliary Cholangitis Ironwood Pharmaceuticals Partnership

CNP-106 Myasthenia Gravis

CNP-103 Type 1 Diabetes

CNP-107 Vitiligo

CNP-105 Immune Thrombocytopenia

CNP-108 T Cell Immunogenicity in Gene & Protein Therapies

Allergy

CNP-201 Peanut Allergy

CNP-101/TAK-101 Celiac Disease

CNP-101/TAK-101 Celiac Disease

Celiac disease is a genetic autoimmune disorder that affects approximately 1% of the global population. In celiac disease, ingestion of gluten leads to damage of the villi in the small intestine causing malabsorption of nutrients. This can lead to long-term health conditions such as nutritional and vitamin deficiencies often precipitating early onset of osteoporosis or osteopenia. Furthermore, it can lead to more malignant conditions such as Non-Hodgkin lymphoma and small intestinal adenocarcinoma. Failure to comply with a gluten-free diet will typically lead to relapse as the underlying pathology of celiac disease remains unaddressed.

COUR has developed CNP-101 otherwise known as TAK-101, a biodegradable nanoparticle encapsulating gliadin proteins – the major component of dietary gluten. CNP-101 is the first investigational agent to induce antigen-specific immune tolerance in any autoimmune disease. In a Phase 2, double-blind, placebo-controlled clinical trial, patients with celiac disease were treated with CNP-101 and, starting one week later, were fed wheat gluten for 14 days. While patients receiving placebo developed severe immune responses to gliadin and damaging inflammation in their small intestine, patients treated CNP-101 showed significantly less inflammation.

In addition, CNP-101 showed a trend toward protecting the intestines from gluten-related injury when compared to untreated patients. Based on these Phase 2 clinical results, Takeda acquired the license to CNP-101 in October 2019 and will lead further clinical development.

Learn more about COUR’s
Autoimmune Disease Programs
Quote Block Decoration

To our knowledge, this is the first clinical trial to demonstrate induction of antigen specific immune tolerance in any autoimmune disease

Ciarán Kelly, Md,
Professor of Medicine at Harvard Medical School
CNP-104 Primary Biliary 
Cholangitis

CNP-104 Primary Biliary
Cholangitis

Biliary Cholangitis is a rare autoimmune disease targeting the liver; it affects 133,000 people in the U.S. PBC is caused by the dysregulated immune response towards proteins of liver bile duct cells which leads to immune-mediated destruction of bile ducts. As a result, bile acids build up progressively in the liver leading to irreversible damage and scarring of the liver tissue ultimately requiring liver transplant. COUR is developing CNP-104, a biodegradable nanoparticle encapsulating PDC-E2. CNP-104 is design to potentially address the underlying dysregulated immune system responsible for disease progression or recovery of the damaged tissue. CNP-104 received Fast Track designation by the FDA in January 2022.

Learn more about COUR’s
Rare Disease Programs

CNP-106 Myasthenia Gravis

Myasthenia Gravis (MG) is a debilitating autoimmune disease affecting the neuromuscular system. In MG, dysregulation of the immune system results in immune mediated destruction of the neuromuscular cells resulting in weakening of the skeletal system. CNP-106 is an antigen specific investigational therapeutic designed to potentially prevent immune mediated neuromuscular destruction. In doing so, CNP-106 aims to reprogram the immune system to address the immunological root cause of disease in Myasthenia Gravis.

Learn more about COUR’s
Rare Disease Programs
CNP-106 Myasthenia Gravis
CNP-103 Type 1 Diabetes

CNP-103 Type 1 Diabetes

Type-1 Diabetes (T1D) is an autoimmune condition driven by immune autoreactivity to proteins found in insulin producing islet cells in the pancreas. Immune mediated destruction of pancreatic islet cells results in loss of insulin production leading to high blood glucose levels which can affect normal functioning of multiple organs in the body. CNP-103 has the potential to address the underlying immunological drivers of T1D and return balance to the immune system via antigen-specific immune reprogramming to stop immune mediated destruction of pancreatic islet cells. COUR believes that the highly specific mechanism of action of CNP-103 could achieve long term therapeutic efficacy without causing broad immune suppression.

Learn more about COUR’s
Autoimmune Disease Programs

CNP-107 Vitiligo

Vitiligo is a chronic skin disorder caused by selective autoimmune destruction of melanocytes which are specialized cells critical for producing the protective skin darkening pigment melanin. The destruction of these cells leads to skin lesions and depigmentation, and in some cases discomfort due to itchy skin. CNP-107 is an antigen specific investigational therapeutic designed to potentially address the underlying immune dysfunction driving vitiligo disease pathology. COUR believes that CNP-107 may prevent autoimmune mediated skin depigmentation allowing for skin re-pigmentation via the body’s normal regenerative processes.

Learn more about COUR’s
Autoimmune Disease Programs
CNP-107 Vitiligo
CNP-105 Immune Thrombocytopenia

CNP-105 Immune Thrombocytopenia Purpura

Immune Thrombocytopenia Purpura (ITP) is a rare autoimmune disease targeting blood cells called platelets which are required for normal blood clotting. This targeting is caused by the dysregulated immune response towards proteins found on the surface of platelets leading to immune-mediated platelet destruction. As a result, ITP patients experience excessive and frequent bleeding and bruising due to extremely low platelet counts in blood. CNP-105 is an investigational therapeutic designed to reprogram the immune system, stopping it from attacking platelets, and allowing platelet levels in blood to be restored to normal levels.

Learn more about COUR’s
Rare Disease Programs

CNP-108 T Cell Immunogenicity in Gene & Protein Therapies

COUR is developing CNP-108, a biodegradable nanoparticle encapsulating AAV protein replacement, which neutralizes antibodies by harnessing the immune system’s learning power to induce the immune system to build a tolerance to gene therapy treatments.

Learn more about COUR’s
Gene Therapy Programs
CNP-108 Gene Therapy

CNP-201 Peanut Allergy

COUR’s lead program in allergy is directed against the growing threat of peanut allergies in adults and children. Peanut allergy affects approximately 3 million Americans. It is characterized by gastrointestinal, respiratory, skin, and systemic manifestations; in extreme cases anaphylaxis occurs and can rapidly become life-threatening. CNP-201 is a biodegradable nanoparticle encapsulating peanut protein. It has the potential to treat patients with peanut allergy by reducing the need for strict peanut avoidance and reducing the potentially fatal health risks associated with peanut allergy. COUR filed an IND for CNP-201 in December 2020.

Learn more about COUR’s
Allergy Program

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2023

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top